303 related articles for article (PubMed ID: 32598477)
21. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
[TBL] [Abstract][Full Text] [Related]
22. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
[TBL] [Abstract][Full Text] [Related]
23. TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present.
Kim DH; Siddiqui S; Jain P; Wang M; Thakral B; Li S; Miranda R; Vega F; Medeiros LJ; Ok CY
Hum Pathol; 2024 Apr; 146():1-7. PubMed ID: 38460798
[TBL] [Abstract][Full Text] [Related]
24.
Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
[TBL] [Abstract][Full Text] [Related]
25. Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Chiron D; Di Liberto M; Martin P; Huang X; Sharman J; Blecua P; Mathew S; Vijay P; Eng K; Ali S; Johnson A; Chang B; Ely S; Elemento O; Mason CE; Leonard JP; Chen-Kiang S
Cancer Discov; 2014 Sep; 4(9):1022-35. PubMed ID: 25082755
[TBL] [Abstract][Full Text] [Related]
26. TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.
Dong HJ; Zhou LT; Fang C; Fan L; Zhu DX; Wang YH; Li JY; Xu W
Med Oncol; 2012 Sep; 29(3):2166-73. PubMed ID: 22057359
[TBL] [Abstract][Full Text] [Related]
27. Divergent clonal evolution of a common precursor to mantle cell lymphoma and classic Hodgkin lymphoma.
Tashkandi H; Petrova-Drus K; Batlevi CL; Arcila ME; Roshal M; Sen F; Yao J; Baik J; Bilger A; Singh J; de Frank S; Kumar A; Aryeequaye R; Zhang Y; Dogan A; Xiao W
Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31395597
[TBL] [Abstract][Full Text] [Related]
28. Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.
Aukema SM; Croci GA; Bens S; Oehl-Huber K; Wagener R; Ott G; Rosenwald A; Kluin PM; van den Berg E; Bosga-Bouwer AG; Hoogendoorn M; Hoster E; Bittmann I; Nagel I; Murga Penas EM; Kreuz M; Bausinger J; Belder W; Oschlies I; Dyer MJS; Jayne S; Siebert R; Klapper W
Virchows Arch; 2021 Jul; 479(1):133-145. PubMed ID: 33528622
[TBL] [Abstract][Full Text] [Related]
29. Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
Klener P; Fronkova E; Berkova A; Jaksa R; Lhotska H; Forsterova K; Soukup J; Kulvait V; Vargova J; Fiser K; Prukova D; Alam M; Calvin Lenyeletse Maswabi B; Michalova K; Zemanova Z; Jancuskova T; Pekova S; Trneny M
Int J Cancer; 2016 Nov; 139(10):2252-60. PubMed ID: 27407063
[TBL] [Abstract][Full Text] [Related]
30. Concurrent
Malarikova D; Berkova A; Obr A; Blahovcova P; Svaton M; Forsterova K; Kriegova E; Prihodova E; Pavlistova L; Petrackova A; Zemanova Z; Trneny M; Klener P
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751805
[TBL] [Abstract][Full Text] [Related]
31. Subclonal evolution of a classical Hodgkin lymphoma from a germinal center B-cell-derived mantle cell lymphoma.
Schneider S; Crescenzi B; Schneider M; Ascani S; Hartmann S; Hansmann ML; Falini B; Mecucci C; Tiacci E; Küppers R
Int J Cancer; 2014 Feb; 134(4):832-43. PubMed ID: 23929122
[TBL] [Abstract][Full Text] [Related]
32. Novel agents for mantle cell lymphoma: molecular rational and clinical data.
Sarkozy C; Ribrag V
Expert Opin Investig Drugs; 2020 Jun; 29(6):555-566. PubMed ID: 32321318
[TBL] [Abstract][Full Text] [Related]
33. An Aggressive Presentation of Mantle Cell Lymphoma With Unique Molecular Features.
Inamdar AA; Loo A; Mikhail N; Lee P
Cureus; 2021 Aug; 13(8):e17598. PubMed ID: 34646650
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.
Jing C; Zheng Y; Feng Y; Cao X; Xu C
Sci Rep; 2021 Jun; 11(1):11896. PubMed ID: 34099776
[TBL] [Abstract][Full Text] [Related]
35. Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.
Gribbin C; Chen J; Martin P; Ruan J
Leuk Lymphoma; 2024 Jan; 65(1):1-13. PubMed ID: 37800170
[TBL] [Abstract][Full Text] [Related]
36. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations.
Che Y; Liu Y; Yao Y; Hill HA; Li Y; Cai Q; Yan F; Jain P; Wang W; Rui L; Wang M
Blood Cancer J; 2023 Feb; 13(1):27. PubMed ID: 36797243
[TBL] [Abstract][Full Text] [Related]
37. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.
Yi S; Yan Y; Jin M; Bhattacharya S; Wang Y; Wu Y; Yang L; Gine E; Clot G; Chen L; Yu Y; Zou D; Wang J; Phan AT; Cui R; Li F; Sun Q; Zhai Q; Wang T; Yu Z; Liu L; Liu W; Lyv R; Sui W; Huang W; Xiong W; Wang H; Li C; Xiao Z; Hao M; Wang J; Cheng T; Bea S; Herrera AF; Danilov A; Campo E; Ngo VN; Qiu L; Wang L
J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 34882582
[TBL] [Abstract][Full Text] [Related]
38. CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma.
Miao Y; Lin P; Wang W; Jeffrey Medeiros L; Lu X
Am J Clin Pathol; 2016 Dec; 146(6):747-752. PubMed ID: 28028120
[TBL] [Abstract][Full Text] [Related]
39. IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome.
Cogliatti SB; Bertoni F; Zimmermann DR; Henz S; Diss TC; Ghielmini M; Schmid U
J Pathol; 2005 Jul; 206(3):320-7. PubMed ID: 15887292
[TBL] [Abstract][Full Text] [Related]
40. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments.
Jain P; Wang ML
Am J Hematol; 2022 May; 97(5):638-656. PubMed ID: 35266562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]